ArticleAJNR. American journal of neuroradiology2021
Article in AJNR. American journal of neuroradiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- MGMT promoter methylation across glioma subtypes: biological relevance, treatment response, and survival outcomes.Molecular biology reports · 2026Review
- Relevance of a complete re-resection of contrast enhancing tumor in MGMT promotor non-methylated versus methylated recurrent glioblastomas.Brain & spine · 2026Article
- Beyond the Promoter: Total MGMT Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma.Molecular cancer therapeutics · 2025Article
- Advanced Distance-Resolved Evaluation of the Perienhancing Tumor Areas with FLAIR Hyperintensity Indicates Different ADC Profiles byAJNR. American journal of neuroradiology · 2025Article
- Neurooncology: 2025 update.Free neuropathology · 2025Review
- Correlations ofMolecular and clinical oncology · 2025Article
- Adaptive fine-tuning based transfer learning for the identification of MGMT promoter methylation status.Biomedical physics & engineering express · 2024Article
- 'The Reports of My Death Are Greatly Exaggerated'-Evaluating the Effect of Necrosis onCancers · 2024Article
- Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives.Biomarker research · 2023Review
- Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study.Korean journal of radiology · 2023Article
- Article
- Validation of MRI-Based Models to Predict MGMT Promoter Methylation in Gliomas: BraTS 2021 Radiogenomics Challenge.Cancers · 2022Article
- Review
- Article
- Increased ASF1B Expression Correlates With Poor Prognosis in Patients With Gliomas.Frontiers in oncology · 2022Article
- Genotoxic therapy and resistance mechanism in gliomas.Pharmacology & therapeutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeMATERIALS AND
methodsBetween January 2008 and November 2016, forty patients with histologically confirmed recurrent glioblastoma were enrolled. Patients were divided into 3 groups according to the
resultsGroup methylated to unmethylated showed significantly higher means and 90th and 95th percentiles of the cumulative normalized relative CBV values of the nonenhancing region of the initial tumor than group methylated and group unmethylated (all
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.